Literature DB >> 7798414

Acral lentiginous melanoma. A histological type without prognostic significance.

N Cascinelli1, S Zurrida, V Galimberti, C Bartoli, R Bufalino, I Del Prato, L Mascheroni, A Testori, C Clemente.   

Abstract

BACKGROUND: Acral lentiginous melanoma (ALM) is reported to have a poorer prognosis than melanomas of other histotypes.
OBJECTIVE: The purpose of this paper is to verify if ALMs, per se, have a more aggressive behavior or if the poorer prognosis of these patients is due to a later diagnosis.
METHODS: Clinical charts of 165 patients with acrally located melanoma were reviewed as well as all histological slides. In all patients, histotype, Clark's level, Breslow thickness, pigmentation, presence of ulceration, and regression were reported. Mitotic index, vascular invasion, and microscopic satellitosis were also determined. Survival of the 64 patients with ALM was compared with survival observed in the remaining 101 acral (nonlentiginous) melanomas.
RESULTS: Melanoma localized at acral sites constitute 8.9% of the 1845 patients with melanoma treated at our Institute from 1975 to 1990. All were Caucasian, 57 were males, and 108 females. Out of the 165 patients with this localization, 64 (38.8%) were classified as ALM. Disease-free and overall survival of the 64 ALM patients were not different at a statistically significant level compared with the areas observed in the other acral nonlentiginous melanoma.
CONCLUSION: The survival difference between ALM and other histological types is due to a later diagnosis and not to a more aggressive behavior of ALM.

Entities:  

Mesh:

Year:  1994        PMID: 7798414     DOI: 10.1111/j.1524-4725.1994.tb03711.x

Source DB:  PubMed          Journal:  J Dermatol Surg Oncol        ISSN: 0148-0812


  10 in total

Review 1.  Diagnosis and Management of Acral Lentiginous Melanoma.

Authors:  Yoshiyuki Nakamura; Yasuhiro Fujisawa
Journal:  Curr Treat Options Oncol       Date:  2018-06-27

Review 2.  Emerging strategies to treat rare and intractable subtypes of melanoma.

Authors:  Gretchen M Alicea; Vito W Rebecca
Journal:  Pigment Cell Melanoma Res       Date:  2020-04-24       Impact factor: 4.693

3.  Analysis of recurrence patterns in acral versus nonacral melanoma: should histologic subtype influence treatment guidelines?

Authors:  Priyanka V Gumaste; Nathaniel H Fleming; Ines Silva; Richard L Shapiro; Russell S Berman; Judy Zhong; Iman Osman; Jennifer A Stein
Journal:  J Natl Compr Canc Netw       Date:  2014-12       Impact factor: 11.908

4.  Acral lentiginous melanoma: incidence and survival patterns in the United States, 1986-2005.

Authors:  Porcia T Bradford; Alisa M Goldstein; Mary L McMaster; Margaret A Tucker
Journal:  Arch Dermatol       Date:  2009-04

5.  Acral lentiginous melanoma in the Turkish population and a new dermoscopic clue for the diagnosis.

Authors:  Fezal Ozdemir; Micol A Errico; Banu Yaman; Isil Karaarslan
Journal:  Dermatol Pract Concept       Date:  2018-04-30

Review 6.  Evidence from Clinical Studies Related to Dermatologic Surgeries for Skin Cancer.

Authors:  Shoichiro Ishizuki; Yoshiyuki Nakamura
Journal:  Cancers (Basel)       Date:  2022-08-08       Impact factor: 6.575

Review 7.  Advanced Acral Melanoma Therapies: Current Status and Future Directions.

Authors:  Yiqun Zhang; Shijie Lan; Di Wu
Journal:  Curr Treat Options Oncol       Date:  2022-09-20

8.  Acral Melanoma in Chinese: A Clinicopathological and Prognostic Study of 142 cases.

Authors:  Jiaojie Lv; Bo Dai; Yunyi Kong; Xuxia Shen; Jincheng Kong
Journal:  Sci Rep       Date:  2016-08-22       Impact factor: 4.379

9.  Comparative Analysis of Acral Melanoma in Chinese and Caucasian Patients.

Authors:  Kai Huang; Yu Xu; Emmanuel M Gabriel; Subhasis Misra; Yong Chen; Sanjay P Bagaria
Journal:  J Skin Cancer       Date:  2020-10-06

10.  Acral lentiginous melanoma-Population, treatment, and survival using the NCDB from 2004 to 2015.

Authors:  Shelly X Bian; Lindsay Hwang; Jennifer Hwang; Omar Ragab; Gino K In; David Peng; Eugene Lin
Journal:  Pigment Cell Melanoma Res       Date:  2021-08-02       Impact factor: 4.693

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.